TW201313208A - 局部貼片清涼製劑 - Google Patents
局部貼片清涼製劑 Download PDFInfo
- Publication number
- TW201313208A TW201313208A TW101143367A TW101143367A TW201313208A TW 201313208 A TW201313208 A TW 201313208A TW 101143367 A TW101143367 A TW 101143367A TW 101143367 A TW101143367 A TW 101143367A TW 201313208 A TW201313208 A TW 201313208A
- Authority
- TW
- Taiwan
- Prior art keywords
- topical patch
- water
- patch preparation
- weight
- cooling agent
- Prior art date
Links
- 230000000699 topical effect Effects 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title abstract description 18
- 238000001816 cooling Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 239000002826 coolant Substances 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 230000009965 odorless effect Effects 0.000 claims abstract description 21
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 12
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 9
- -1 acyclic amide Chemical class 0.000 claims description 7
- FYNXOZOQSPWTPU-UHFFFAOYSA-N n,2,3-trimethyl-2-propan-2-ylbutan-1-amine Chemical group CNCC(C)(C(C)C)C(C)C FYNXOZOQSPWTPU-UHFFFAOYSA-N 0.000 claims description 6
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 claims description 4
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 2
- 125000002015 acyclic group Chemical group 0.000 claims 2
- 239000000853 adhesive Substances 0.000 abstract description 18
- 230000001070 adhesive effect Effects 0.000 abstract description 12
- 239000000499 gel Substances 0.000 description 26
- 239000000463 material Substances 0.000 description 16
- 239000011159 matrix material Substances 0.000 description 16
- 239000000126 substance Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- RWAXQWRDVUOOGG-UHFFFAOYSA-N N,2,3-Trimethyl-2-(1-methylethyl)butanamide Chemical compound CNC(=O)C(C)(C(C)C)C(C)C RWAXQWRDVUOOGG-UHFFFAOYSA-N 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 7
- 239000000017 hydrogel Substances 0.000 description 7
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 239000006184 cosolvent Substances 0.000 description 5
- 229920000139 polyethylene terephthalate Polymers 0.000 description 5
- 239000005020 polyethylene terephthalate Substances 0.000 description 5
- 230000000451 tissue damage Effects 0.000 description 5
- 231100000827 tissue damage Toxicity 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010072170 Skin wound Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- 235000019645 odor Nutrition 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- VUNOFAIHSALQQH-UHFFFAOYSA-N Ethyl menthane carboxamide Chemical compound CCNC(=O)C1CC(C)CCC1C(C)C VUNOFAIHSALQQH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000035597 cooling sensation Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940045136 urea Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LMXFTMYMHGYJEI-IWSPIJDZSA-N (1R,2R,5R)-2-(1-hydroxy-1-methylethyl)-5-methylcyclohexanol Chemical compound C[C@@H]1CC[C@@H](C(C)(C)O)[C@H](O)C1 LMXFTMYMHGYJEI-IWSPIJDZSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- MDVYIGJINBYKOM-IBSWDFHHSA-N 3-[(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl]oxypropane-1,2-diol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OCC(O)CO MDVYIGJINBYKOM-IBSWDFHHSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- NFJVCXVGMKMUAT-UHFFFAOYSA-H C(C)(=O)[O-].C(C)(=O)[O-].C(C)(=O)[O-].O[Al+]O.C(C)(=O)[O-].[Al+3] Chemical compound C(C)(=O)[O-].C(C)(=O)[O-].C(C)(=O)[O-].O[Al+]O.C(C)(=O)[O-].[Al+3] NFJVCXVGMKMUAT-UHFFFAOYSA-H 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 241000282602 Colobus Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229920006266 Vinyl film Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- UJNOLBSYLSYIBM-SGUBAKSOSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] 2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C(C)O UJNOLBSYLSYIBM-SGUBAKSOSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940048053 acrylate Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000010624 camphor oil Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960001673 diethyltoluamide Drugs 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- WPFVBOQKRVRMJB-UHFFFAOYSA-N hydroxycitronellal Chemical compound O=CCC(C)CCCC(C)(C)O WPFVBOQKRVRMJB-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 230000036575 thermal burns Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/10—Cooling bags, e.g. ice-bags
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/10—Cooling bags, e.g. ice-bags
- A61F7/106—Cooling bags, e.g. ice-bags self-cooling, e.g. using a chemical reaction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0001—Body part
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0098—Heating or cooling appliances for medical or therapeutic treatment of the human body ways of manufacturing heating or cooling devices for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
- A61F2013/0296—Apparatus or processes for manufacturing adhesive dressings or bandages for making transdermal patches (chemical processes excluded)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Thermal Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
Abstract
提供一種含無氣味生理清涼劑的局部貼片製劑,及其使用方法。本發明之局部貼片製劑係由置於支撐物上的黏性凝膠組合物所構成,該黏性凝膠組合物含有無氣味生理清涼劑、水溶性聚合物凝膠、水及保水劑。在使用本發明之局部貼片製劑時,將局部貼片製劑貼敷於患者的皮膚表面並在該患部上維持足以投與有效劑量之無氣味生理清涼劑至患者的一段時間。本發明可應用於各種的用途。
Description
提供一種含無氣味生理清涼劑的局部貼片製劑,及其使用方法。本發明之局部貼片製劑係由置於支撐物上的黏性凝膠組合物所構成,該黏性凝膠組合物含有無氣味生理清涼劑、水溶性聚合物凝膠、水及保水劑。在使用本發明之局部貼片製劑時,將局部貼片製劑貼敷於患者的皮膚表面並在該患部上維持足以投與有效劑量之無氣味生理清涼劑至患者的一段時間。本發明可應用於各種的用途。
根據35U.S.C.§119(e),此專利申請案主張2005年1月4日申請的美國臨時專利申請案序號60/641,482之申請日的優先權,將其揭示於此以供參考。
互相關聯之生理事件會造成組織的發炎。伴隨組織損傷的皮膚發炎導因於各種的皮膚疾病如濕疹、乾癬、脂漏性皮膚炎(seborrheic dermatitis)、接觸性皮膚炎、過敏性皮膚炎等。炎症亦和導因於紫外線或熱灼傷、某種微生物的侵犯、昆蟲叮咬傷等之組織損傷有關。和組織損傷有關之肌肉、韌帶、滑液囊和關節的深層組織發炎可導因於物理性創傷如扭傷、拉傷、挫傷、激烈運動等。此類的發炎將導致滑囊炎、肌腱炎及肌肉酸痛。發炎亦和導因於代謝性
疾病如痛風,或導因於免疫性疾病如類風濕性關節炎,或導因於年齡的成長如骨關節炎的組織損傷有關。
發炎的症狀為紅斑(潮紅)、水腫(腫脹)、發熱、疼痛,以及功能喪失。組織損傷的立即後果為釋出仲介炎症的某種化學物質,即引起及強化潮紅、腫脹、疼痛及發熱之症狀的物質。這些物質的實施例為組織胺、血清素(serotonin)及激肽(kinins)。
目前已利用各種的局部貼片製劑以減緩疼痛如肩膀僵硬、背痛、發炎等等。這些局部貼片製劑通常利用具有清涼效果之抗刺激劑的薄荷醇、樟腦和薄荷油作為其活性成分。然而,這些清涼劑會產生不適的強烈味道。
因此,仍亟需發展一種可有效治療上述疾病的新穎局部清涼劑組合物。
美國專利號碼4,296,255;4,296,093;4,230,688;4,226,988;4,193,936;4,153,679;4,150,052;4,070,496;4,070,449;4,060,091;4,059,118;4,034,109;4,033,994;4,032,661;4,020,153;5,266,592;4,459,425;5,773,410;6,267,974;6,592,884;5,959,161;6,328,982;6,359,168;6,214,788;5,608,119;6,769,428;6,455,080;6,656,456;6,821,507;6,740,311;6,677,391;6,497,859;6,769,428和6,719,995;日本專利號碼2004059474;美國專利申請案號20040067970。
提供一種含無氣味生理清涼劑的局部貼片製劑,及其使用方法。本發明之局部貼片製劑係由置於支撐物上的黏性凝膠組合物所構成,該黏性凝膠組合物含有無氣味生理清涼劑、水溶性聚合物凝膠、水及保水劑。在使用本發明之局部貼片製劑時,將局部貼片製劑貼敷於患者的皮膚表面並在該患部上維持足以投與有效劑量之無氣味生理清涼劑至患者的一段時間。本發明可應用於各種的用途。
提供一種含無氣味生理清涼劑的局部貼片製劑,及其使用方法。本發明之局部貼片製劑係由置於支撐物上的黏性凝膠組合物所構成,該黏性凝膠組合物含有無氣味生理清涼劑、水溶性聚合物凝膠、水及保水劑。在使用本發明之局部貼片製劑時,將局部貼片製劑貼敷於患者的皮膚表面並在該患部上維持足以投與有效劑量之無氣味生理清涼劑至患者的一段時間。本發明可應用於各種的用途。
在進一步說明本發明之前,應瞭解本發明並非僅侷限於所述的特定具體例,因此其必然有許多不同的變化。由於本發明範圍僅限於申請專利範圍附件,因此亦應瞭解此處使用之名詞僅為說明特定具體例之用途而非為侷限性的用法。
當提供一範圍之值時,應瞭解除非另外明述,該範圍
上下限間之各居間值至其居間值之單位下限的十位數及該陳述範圍內的任何其他陳述值或居間值仍被包含於本發明的範圍內。這些較小範圍的上下限值可被獨立包含於較小範圍內,並且若該陳述範圍無任何特殊的排除限制,則其亦被包含於本發明的範圍內。當陳述範圍包含一或兩種限制值時,不包含其一或兩種限制值的範圍亦包含於本發明的範圍內。
此處所陳述的方法可依邏輯上可行之任何順序以及所列舉之順序下進行。
除非另有說明,否則此處使用之全部技術和科學名詞和熟習本技藝之人仕對本發明領域內通常所瞭解的意義相同。雖然此處所述之任何類似或相同的方法和材料亦可被應用於本發明之實務或試驗中,但仍於下文中詳述其較佳的方法和材料。
納於此處作為參考之全部述及的專利說明其目的為揭示和描述專利說明內所述及可能和本發明有關的方法和/或材料。
應注意者為除非本文中另有明述,否則用於此處及申請專利範圍附件內的單數形式亦包括複數涵意。其進一步應注意申請專利範圍已排除任何選擇性的元件。依此,此聲明可做為所述專利申請元件有關之"專屬"、"唯一"等專有名詞之使用的前置基礎,或做為否定性的限制。
此處的公開資料僅提供作為在本專利之申請日期前揭示的用途。其不得因此推斷本發明已承認其為瓢竊自先前
的發明而喪失優先於該公開資料的權利。此外,所述之公告日期可能和實際之公告日期有所不同,因此必需自行加以確認。
如上所述,本發明係關於一種無氣味生理清涼劑之局部貼片製劑。本發明之局部貼片製劑的特徵為具有在凝膠黏性基質內之有效劑量的無氣味生理清涼劑。第1圖係根據本發明所述之局部貼片製劑。從第1圖中可看出此代表性局部貼片製劑10含有置於支撐物14上的凝膠黏性基質12。現在更詳細描述其各別的成分。
作為滯留層的凝膠黏性基質係由溶解於或分散於黏性凝膠基質內的無氣味生理清涼劑所製成。”生理清涼劑”指當接觸皮膚時可使患者產生類似薄荷清涼劑之清涼感覺或效果的物質。”無氣味”指該物質之氣味較薄荷之氣味刺激性為低。
WS-3:(N-乙基-對-甲烷-3-甲醯胺),供應自Millennium化學公司
WS-23:(N,2,3-三甲基-2-異丙基丁醯胺),供應自Millennium
化學公司
Frescolat ML:(-)-乳酸薄荷酯,供應自Haarmann & Reimer公司
在某些具體例中,清涼劑係一種非環狀醯胺,其代表性非環醯胺包括下式之化合物:
其中R1、R2和R3係各為C1~C5烷基及全部總共至少3個碳原子,如從約3~10個包括從約5~10個碳原子;以及R’係C1~C5烷基、最多8個碳原子的C1~C8羥烷基或烷基羧烷基。在代表性具體例中R1為甲基、乙基或正丙基及R2和R3中之一或二者在相對標示(*)碳原子之α或β位置為分支。在代表性具體例中,清涼劑為N,2,3-三甲基-2-異丙基丁醯胺(亦稱為WS-23;N,2,3-三甲基-2-異丙基丁醯胺,CAS# 51115-67-4)。
可利用任何適當的方法製造上述的化合物,其代表性方法述於美國專利號碼4,296,255。
其他適合的代表性無氣味生理清涼劑包括,但不侷限於:芳樟醇(linalool)、香葉醇(geraniol)、羥基香茅醛(hydroxycitronellal)、WS-3(Millennium化學公司)、Flescolat MGA(Haarman & Reimer公司)、Flescolat ML(Haarman & Reimer公司)、PMD38(Takasago公司)、CoolactP(Takasago
公司)以及清涼劑10(Takasago公司)等。
黏性凝膠基質內之無氣味生理清涼劑的含量為貼附於皮膚時足以施予有效量之清涼劑的用量,其將詳述於下文。在許多具體例中,黏性凝膠基質內之無氣味生理清涼劑的含量為從約0.1至15.0%(重量/重量),有時從約0.5至10.0%(重量/重量),例如從約1.0至8.0%(重量/重量)以及包括從約2.0至7.0%(重量/重量)。
含如上述之清涼劑的黏性凝膠基質係由水溶性高分子量物質、水和保水劑所製成。在某些具體例中,黏性凝膠基質可進一步含有共溶劑,例如有機共溶劑。現在更詳細地說明其各別的成分。
適合的水溶性高分子量物質包括水溶性聚合物,適合的聚合物包括但不侷限於:明膠、澱粉、瓊脂、甘露聚糖、褐藻酸(alginic acid)、聚丙烯酸、聚丙烯酸鈉、糊精、甲基纖維素、甲基纖維素鈉、羥丙基纖維素、羧甲基纖維素鈉、纖維素膠、羧乙烯聚合物、聚乙烯醇、聚乙烯吡咯啶酮、阿拉伯膠、金合歡膠(acacia)、黃蓍樹膠、刺梧桐膠(karaya gum),以及澱粉丙烯酸酯共聚物或其他澱粉丙烯酸鈉接枝共聚物。亦可使用其金屬鹽類,以及藉由有機或無機交聯劑所產生的交聯產物。可利用這些水溶性聚合物產生用於黏性凝膠組合物內之其他起始材料的性質和特性,其在實務上可單獨使用或結合二或多種聚合物共同使用。黏性凝膠基質內之高分子量物質的含量通常從約0.5至20%(重量/重量),例如從約2至20%(重量/重量)。
水雖然可作為水的成分,但是本發明的許多較佳具體例中以使用蒸餾水或離子交換水或其類似物較佳。凝膠黏著劑內的水分含量應足以賦予凝膠黏著劑所需的物理性質,以及促進皮膚角質或角質層的膨脹因而改善活性劑的通透性或穿透性,其於凝膠組合物內的水分含量通常為從約10至80%,例如從約30至60%(重量/重量)。
黏性凝膠組合物內之保水劑(water-retaining)或持水劑(water-holding)係可避免黏性凝膠基質內水分的揮發而使其含量在儲存和使用過程中基本上維持恒定。組合物內可使用一或多種保水劑,黏性凝膠基質內之保水劑的含量為從約1至70%重量比,例如從約10至60%。適合的保水劑或持水劑包括但不侷限於:一或多種的多價或多元糖或醇,例如甘油、山梨糖醇、丙二醇、二乙二醇、1,3-丁二醇,以及乙二醇等。
此外,本發明之凝膠基質組合物亦可含有共溶劑,該共溶劑通常為一有機共溶劑。適合的共溶劑包括但不侷限於:n-甲基-2-吡咯啶酮、二乙基甲苯醯胺(DEET)、乙醇、甲醇、聚乙二醇(例如低分子量聚乙二醇如PEG600或更低如500、400、300、200、100等及其混合物),以及肉豆蔻酸二異丙酯等。可由單一成分製成共溶劑或結合二或多種以上的成分。
此外,除上述成分之外需要時亦可混合一般局部水溶性貼片製劑所使用的各種添加物,其包括無機物如陶土、膨潤土以及二氧化鈦;防腐劑如對羥基苯甲酸酯
(paraben);陰離子、陽離子和非離子表面活性劑;金屬鋁交聯劑如氯化鋁、乾燥氫氧化鋁凝膠和二羥基胺基乙酸鋁;油類如荷荷芭油(jojoba oil)及蓖麻油;螯合劑如EDTA;pH調節劑如蘋果酸、酒石酸及二異丙醇胺;酒精如乙醇;保濕劑如玻尿酸、蘆薈萃取物及尿素;以及其他香料和著色劑。
凝膠基質組合物的pH一般在生理可接受的範圍內,其pH一般從約4.0至7.0,例如從約4.0至6.0。
如上所述,含一或多種活性成分的黏性凝膠組合物一般置於支撐物或襯墊上。支撐物通常由配合人體活動的彈性材料所製成,其包括例如各種不織布、針織布、伸縮布、絨布,或上述材料層合聚乙烯薄膜、聚對苯二甲酸乙二醇酯薄膜、聚氯乙烯薄膜、乙烯醋酸乙酯共聚物薄膜、聚胺基甲酸酯(polyurethane)薄膜等。
除黏性凝膠組合物和支撐層之外,本發明之局部貼片亦可包括和背襯相對的凝膠層表面上之可撕離層16,其可使凝膠層和外界環境隔開而達到保護的效果。可撕離層可由任何適合的材料製成,代表性的可撕離層材料包括聚酯如PET或PP等。
在許多具體例中,其貼片係置於密封包裝內。通常,密封包裝係由一層能避免水分、氧氣和其他物質透過的材料所製成,即包裝含有水分/氧氣阻隔材料。可利用任何適合的阻隔材料,適合的阻隔材料包括金屬層如鋁,而在許多具體例中,其阻隔層為一鋁箔層。阻隔層具有足夠提供
阻隔功能的厚度,其厚度一般從約5至15微米,一般從約6至10微米。在許多具體例中,其包裝為層合一或多種其他層如聚合物層、紙質層等的阻隔層。可用於本發明貼片製劑之含鋁箔材料的代表性包裝為Dainippon印刷公司(Kyoto,日本)所出售的產品。
可利用任何適合的方法製造局部貼片製劑。一種適合用於製造本發明之貼片的方法包括經由均勻混合上述成分製備凝膠黏著劑然後將黏著劑塗覆於支撐物上,接著將製成的產品切割成適當的大小而獲得所需的局部貼片製劑。然後利用如上述含鋁箔層的包裝材料以數片為一單位熱封產生的局部貼片製劑而獲得密封局部貼片。更詳細的製造方法請看美國專利號碼5,827,529;將其納入於此以供參考。
在一代表性的製造方法中,藉由任何適合的方法利用攪拌機將上述成分均勻混合入黏著劑而製成本發明的基質,然後藉由撒佈機將其塗覆於襯墊或支撐材料。如上所述,支撐材料可為例如紙、或以PET或PP或其他聚酯纖維製成的針織或不織布。基於保護,其表面覆蓋以聚酯如PET或PP的可撕離層。這些步驟說明於第2圖。
如下述更詳細的說明,在代表性具體例中水凝膠貼片組合物為自黏性,即具有固有的黏性,因此可固定於皮膚傷口的位置上,即可撕除地附著於皮膚傷口上,而不需在調配物內加入其他黏著劑或利用其他方法將貼片固定位。例如,水凝膠組合物基質可本身即具有黏性。
在代表性具體例中,水凝膠組合物具有以日本工業標準(JIS)Z-0237之黏性強度測量法(請看例如2004年12月1日提出題目為”用於治療皮膚傷口的方法及組合物”之美國專利申請序號60/615,320;將其揭示於此以供參依)所測定的黏度。若已知水凝膠組合物至少可依此方法阻滯在3號球時則認為具有黏性,例如至少約在4號球,包括至少約在5號球。在某些具體例中,組合物具有阻滯在6號球或以上的足夠黏性,例如在7號球或以上、8號球或以上、9號球或以上。在某些具體例中,本組合物具有不同的黏性,其對無生命物質比生命物質較有黏性。
在某些具體例中,本水凝膠貼片組合物利用不同的黏度如黏著性襯墊等或藉由固有黏性結合其他不同黏著劑的方法而可使其固定於皮膚傷口的位置。
本發明可配合及應用某些水凝膠貼片組合物。適合用於本發明之代表性水凝膠貼片組合物包括,但不侷限於,述於PCT國際申請案號WO 02/078757和WO 02/078756以及美國專利號碼5,120,544、5,160,328、5,270,258、5,423,737、5,476,443、5,489,262、5,501,661、5,827,529、6,039,940、6,096,333、6,214,374、6,296,869、6,348,212、6,455,065;將其揭示於此以供參考。
然後將製成之產品切割成特定的大小而獲得所需的局部貼片製劑組合物。貼片可具有不同的形狀,其代表性形狀包括方形、長方形、楕圓形、圓形等。貼片亦可有不同的大小,在許多具體例中其大小從約1至200平方釐米,
以及在許多具體例中從約10至180平方釐米,通常為從約100至150平方釐米,例如140平方釐米。終局部貼片內之基質的重量可從約300至約1500克/平方米,例如從約600至約1200克/平方米。然後將水溶性局部貼片製劑熱封於具有一鋁箔層的包裝材料內而獲得如第3圖所示的成品。
應注意上述僅為代表性的製造方法。任何可製造本發明之局部貼片製劑的方法均可用於本發明。
可利用本貼片製劑輸送清涼劑至一個體,其特別指一個體的皮膚。本發明之貼片特別可貼附於皮膚的任何適當部位。適當的局部位置包括但不侷限於手臂、大腿、軀幹、頭部等。局部貼片製劑之覆蓋表面積必需能供應足夠量的藥劑,在許多具體例中為從約1至200平方釐米,以及在許多具體例中為從約10至180平方釐米,通常為從約100至150平方釐米,例如140平方釐米。
在代表性具體例中,輸送所需劑量之藥劑的時間一般不超過約48小時,通常不超過約24小時。然而,在許多具體例中,製劑維持在貼附部位的時間至少約30分鐘,通常至少約1小時。
本方法在實際操作時,一已知時間內局部貼片可進行單次貼敷或多次貼敷,例如在治療疾病的過程中在一已知時間內使用複數個貼片進行每日一次、每週一次、兩周一次、每月一次等的貼敷。
任何需要投與生理清涼劑至一個體時可使用上述的貼片和方法。根據本發明所述之清涼劑的局部使用方法可有效治療炎症、疼痛等,其包括本專利申請之引言中所述的疾病。通常該個體為”哺乳類”或”哺乳動物”,通常其泛稱屬於哺乳類的有機體,其包括肉食目(犬和貓)、齧齒目(如小白鼠、天竺鼠和大鼠),以及靈長目(如人類、黑猩猩和猿猴)。在許多具體例中,其使用對象為人類。
在代表性具體例中,本方法可用於治療疾病的症狀。治療意指至少可減輕一種侵犯病人之病理性疾病的有關症狀,其減輕在廣義而言指至少降低和治療之病理性疾病有關的參數如症狀及和其有關的副作用。依此,治療亦包括完全抑制如預防其發生或停止如終止病理性疾病或至少一種和其有關的症狀,因而使病人不再受該疾病之苦,或至少不再發生該病理性疾病的特徵性症狀。依此,治療包括治癒及該疾病之症狀的管理。
本發明亦提供套組,本套組至少包括一或多片如上所述之局部貼片製劑。套組內的局部貼片製劑如上述可置於一包裝袋內。套組之局部貼片一般為置於獨立的小袋或類似的包裝容器內以在使用前保存貼片的組合物。本套組一般亦具有如何使用貼片的說明書,該說明書一般述及貼片的使用位置、貼敷方法等有關的資訊。說明書一般記錄在一適當的媒體上。例如,說明書可印刷於如紙張或塑膠片等的基板上。依此,說明書可置於套組內作為包裝附頁、
在套組或其元件(即包裝或子包裝的附件)之容器的標簽內等。在其他具體例中,說明書輸入於電腦可讀取儲存媒體之電子資料檔內,例如CD-ROM、磁碟等。
提供下列實際及比較實施例作為說明,但本發明的範圍並非僅限於這些實施例。
製備已混合5%和7%含量之WS-23的水溶性聚合物局部貼片製劑。均勻地混合WS-23與表1中所述的成分並調製成膏劑,然後以1000克/平方米的重量分佈於PET不織布上,接著以PP薄膜層疊於成品再切割成10釐米x14釐米的大小。
*全部值以%(重量/重量)之單位表示。
實際實施例01中測量WS-23含量的穩定性資料以及貼片黏著劑的強度。其和視為100%之最初值的比較結果示於表2。
*黏著劑強度測量法:日本工業標準(JIS)Z-0237。
將實際實施例01之WS-23局部貼片製劑貼敷於患有肩
膀僵硬、背痛、肌肉疲勞性疼痛和腕道正中神經症候群(CTS)的志願者以測定其效力。
將實際實施例01之WS-23局部貼片製劑貼敷於四位志願者的患部12小時。
測量各患者在貼敷前及貼敷30分鐘後的疼痛程度。
其結果列於下述表3。
10:失去功能,必需處理
08:嚴重,注意力無法集中及無法操作簡單事務
06:中度,但仍能進行某種程度的活動
04:可忍受,有時可能被忽略
02:輕微,感覺到輕微的不適
從上述的結果和討論可顯示本發明提供一種重要之新穎清涼感覺的抗刺激性局部貼片組合物,其組合物優於目前的局部調配物,包括不再有令人不適的氣味。依此,本發明在技藝上具有明顯的貢獻。
納入此專利說明書中所引述的全部公告及專利以供參
考,並將各獨立公告或專利視為被納入此做為參考之明確及獨立敘述的說明。任何引證之公開資料若已揭示於本申請日之前時,並不得因此推斷本發明已承認為瓢竊自先前的發明而喪失先於該公開資料的權利。
上述發明雖然藉由圖表及實施例進行詳細說明,但其僅為便於瞭解之目的,熟習本技藝之人仕極明顯可藉由本發明之提示而進行某種程度的變化和修改,但其仍未超出附加之專利申請的精神或範圍。
10‧‧‧局部貼片製劑
12‧‧‧凝膠黏性基質
14‧‧‧支撐物或襯墊
16‧‧‧可撕離層
第1圖係根據本發明一具體例之局部貼片製劑的橫剖面圖;第2和3圖係根據本發明一具體例之局部貼片劑劑製造方法的示意圖。
10‧‧‧局部貼片製劑
12‧‧‧凝膠黏性基質
14‧‧‧支撐物或襯墊
16‧‧‧可撕離層
Claims (10)
- 一種局部貼片製劑,其包含:含有無氣味生理清涼劑的黏性凝膠組合物;以及一支撐物。
- 如申請專利範圍第1項之局部貼片製劑,其中該無氣味生理清涼劑係非環狀醯胺。
- 如申請專利範圍第2項之局部貼片製劑,其中該非環狀醯胺係為下式:
其中:R’、R1、R2和R3係各為C1~C5烷基。 - 如申請專利範圍第3項之局部貼片製劑,其中該非環狀醯胺係N,2,3-三甲基-2-異丙基丁醯胺。
- 如申請專利範圍第4項之局部貼片製劑,其中該N,2,3-三甲基-2-異丙基丁醯胺在該黏性凝膠組合物內的含量係從約0.1至15.0%(重量/重量)。
- 如申請專利範圍第1項之局部貼片製劑,其中該黏性凝膠組合物含有:水溶性聚合物凝膠;水;以及保水劑。
- 如申請專利範圍第6項之局部貼片製劑,其中該水的含量係從約10至80%(重量/重量)。
- 如申請專利範圍第1項之局部貼片製劑,其中該黏性凝膠組合物的pH係在約4.0至7.0的範圍內。
- 一種局部貼片製劑,其包含:(a)具有pH在約4.0至7.0之範圍內的黏性凝膠組合物並且含有:(i)含量從約0.1至15.0%(重量/重量)的N,2,3-三甲基-2-異丙基丁醯胺;(ii)水溶性聚合物凝膠;(iii)含量從約10至80%(重量/重量)的水;以及(iv)保水劑;以及(b)支撐物。
- 如申請專利範圍第9項之局部貼片製劑,其中該N,2,3-三甲基-2-異丙基丁醯胺的含量係從約0.5至10.0%(重量/重量)。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64148205P | 2005-01-04 | 2005-01-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201313208A true TW201313208A (zh) | 2013-04-01 |
Family
ID=36647805
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095100121A TWI428122B (zh) | 2005-01-04 | 2006-01-03 | 局部貼片清涼製劑及使用其之方法 |
| TW101143367A TW201313208A (zh) | 2005-01-04 | 2006-01-03 | 局部貼片清涼製劑 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095100121A TWI428122B (zh) | 2005-01-04 | 2006-01-03 | 局部貼片清涼製劑及使用其之方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8105624B2 (zh) |
| EP (1) | EP1833443B1 (zh) |
| JP (2) | JP5117196B2 (zh) |
| KR (3) | KR20070102674A (zh) |
| CN (2) | CN101094630B (zh) |
| AR (1) | AR055552A1 (zh) |
| AT (1) | ATE534357T1 (zh) |
| AU (1) | AU2005323206C1 (zh) |
| BR (1) | BRPI0519748A2 (zh) |
| CA (1) | CA2591867C (zh) |
| DK (1) | DK1833443T3 (zh) |
| ES (1) | ES2377134T3 (zh) |
| MX (1) | MX2007008154A (zh) |
| NZ (1) | NZ556202A (zh) |
| PL (1) | PL1833443T3 (zh) |
| PT (1) | PT1833443E (zh) |
| RU (1) | RU2375049C2 (zh) |
| SI (1) | SI1833443T1 (zh) |
| TW (2) | TWI428122B (zh) |
| WO (1) | WO2006073767A1 (zh) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005323206C1 (en) | 2005-01-04 | 2010-01-07 | Teikoku Pharma Usa, Inc. | Cooling topical patch preparation |
| MX2008000486A (es) * | 2005-10-24 | 2008-03-07 | Teikoku Pharma Usa Inc | Composiciones topicas para el alivio del dolor de n-2,3-trimetil-2-isopropilbutamida y metodos para usar las mismas. |
| US20090110656A1 (en) * | 2007-10-31 | 2009-04-30 | Lemke Sarah A | Skin cooling composition |
| US20090157153A1 (en) * | 2007-12-13 | 2009-06-18 | Sarah Anne Lemke | Skin cooling system |
| BRPI0819488B1 (pt) | 2007-12-28 | 2018-07-10 | 3M Innovative Properties Company | Dispositivo de terapia |
| US20110237674A1 (en) * | 2008-10-16 | 2011-09-29 | Novartis Ag | Topical nsaid compositions having sensate component |
| US20100099766A1 (en) * | 2008-10-16 | 2010-04-22 | Novartis Ag | Topical NSAID compositions having sensate component |
| KR20120118495A (ko) * | 2010-04-21 | 2012-10-26 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 국부 마취제 에멀전 조성물 및 이의 제조 및 사용 방법 |
| KR101474210B1 (ko) * | 2012-11-13 | 2014-12-17 | 주식회사 제닉 | 스티키 하이드로겔 화장료 조성물 |
| US9855211B2 (en) | 2013-02-28 | 2018-01-02 | Novan, Inc. | Topical compositions and methods of using the same |
| EP3030266B1 (en) | 2013-08-08 | 2020-10-28 | Novan Inc. | Topical compositions and methods of using the same |
| US10322081B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
| US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
| EP3177262A4 (en) | 2014-08-08 | 2018-04-18 | Novan Inc. | Topical emulsions |
| US20180296497A1 (en) | 2014-10-31 | 2018-10-18 | Avent, Inc. | Method and Articles for Inhibiting Bladder Contractions |
| US10143250B2 (en) * | 2014-11-07 | 2018-12-04 | Richard R. W. Schulz | Removable clothing patches and associated methods |
| CN104644324A (zh) * | 2015-03-17 | 2015-05-27 | 上海易舜冰袋有限公司 | 新型黏土冷热敷袋的制作方法 |
| EP3356356B1 (en) | 2015-10-01 | 2021-05-26 | Firmenich Incorporated | Compounds useful as modulators of trpm8 |
| EP3423100A4 (en) | 2016-03-02 | 2019-10-16 | Novan, Inc. | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION AND METHOD FOR THE TREATMENT THEREOF |
| WO2017180822A1 (en) | 2016-04-13 | 2017-10-19 | Novan, Inc. | Compositions, systems, kits, and methods for treating an infection |
| CN106137536A (zh) * | 2016-07-29 | 2016-11-23 | 吴江富凯医用卫生用品有限公司 | 一种降温型医用绷带 |
| KR102039701B1 (ko) * | 2017-01-19 | 2019-11-26 | 주식회사 리포바이오메드 | 아토피성 질환을 포함하는 혈장 단백질의 삼출성 피부질환의 완화 및 치료용 패드 |
| US20190231663A1 (en) * | 2018-01-31 | 2019-08-01 | L'oreal | Cooling gel composition |
| US11364183B2 (en) | 2018-04-30 | 2022-06-21 | L'oréal | Cosmetic system containing an applicator and a gel composition |
| US20220378607A1 (en) * | 2021-06-01 | 2022-12-01 | Kobayashi Pharmaceutical Co., Ltd. | Adhesive sheet |
| FI20235289A1 (en) | 2023-03-13 | 2024-09-14 | Kl Tech Oy | Self-heating and/or -cooling thermal layer and a product containing such a layer |
| CN117064626A (zh) * | 2023-08-21 | 2023-11-17 | 浙江银达生物技术有限公司 | 一种医用水凝胶贴 |
| US12514756B1 (en) | 2024-10-08 | 2026-01-06 | Covidien Lp | Dermal patch and systems, kits, and methods associated therewith |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4193936A (en) | 1971-02-04 | 1980-03-18 | Wilkinson Sword Limited | N-substituted paramenthane carboxamides |
| US4150052A (en) | 1971-02-04 | 1979-04-17 | Wilkinson Sword Limited | N-substituted paramenthane carboxamides |
| PH10359A (en) | 1971-02-04 | 1977-01-05 | Wilkinson Sword Ltd | N-substituted-p-methane-3-carboxamides having physiological cooling activity and compositions containing them |
| US4033994A (en) | 1972-01-28 | 1977-07-05 | Wilkinson Sword Limited | Substituted p-menthanes |
| US4060091A (en) | 1972-01-28 | 1977-11-29 | Wilkinson Sword Limited | Tobacco and tobacco-containing manufactures containing an ingredient having physiological cooling activity |
| US4059118A (en) | 1972-01-28 | 1977-11-22 | Wilkinson Sword Limited | Tobacco and tobacco-containing manufactures containing an ingredient having physiological cooling activity |
| US4153679A (en) | 1972-04-18 | 1979-05-08 | Wilkinson Sword Limited | Acyclic carboxamides having a physiological cooling effect |
| GB1421743A (en) * | 1972-04-18 | 1976-01-21 | Wilkinson Sword Ltd | Ingestible topical and other compositions |
| BE802469A (fr) | 1972-07-20 | 1974-01-18 | Wilkinson Sword Ltd | Perfectionnements apportes et/ou relatifs a des composes exercant un effet refrigerant physiologique et compositions contenant ceux-ci |
| CA1027347A (en) | 1972-07-20 | 1978-03-07 | David G. Rowsell | Compounds having a physiological cooling effect and compositions containing them |
| GB1434728A (en) | 1972-09-27 | 1976-05-05 | Wilkinson Sword Ltd | Compositions and articles containing phospine oxides having a physiological cooling effect and phosphine oxides for use therein |
| US4070449A (en) | 1972-10-24 | 1978-01-24 | Wilkinson Sword Limited | Compounds having a physiological cooling effect and compositions containing them |
| US4034109A (en) | 1973-01-18 | 1977-07-05 | Wilkinson Sword Limited | Compounds having a physiological cooling effect and compositions containing them |
| US4296093A (en) | 1973-04-16 | 1981-10-20 | Wilkinson Sword Limited | Cyclic carboxamides having a physiological cooling effect |
| US4172887A (en) * | 1973-11-30 | 1979-10-30 | L'oreal | Hair conditioning compositions containing crosslinked polyaminopolyamides |
| JPS5888334A (ja) | 1981-11-20 | 1983-05-26 | Takasago Corp | 3−l−メントキシプロパン−1、2−ジオ−ル |
| US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| DE4110973A1 (de) | 1991-04-05 | 1992-10-08 | Haarmann & Reimer Gmbh | Mittel mit physiologischem kuehleffekt und fuer diese mittel geeignete wirksame verbindungen |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| AU4530493A (en) * | 1992-06-17 | 1994-01-04 | Procter & Gamble Company, The | Coolant compositions with reduced stinging |
| DE69411726T2 (de) | 1993-04-30 | 1999-02-11 | The Procter & Gamble Co., Cincinnati, Ohio | Zusammensetzungen zur freigabe einer aromatischen substanz in die nase |
| US5760085A (en) | 1993-04-30 | 1998-06-02 | The Procter & Gamble Company | Topical aromatic releasing compositions |
| JP2978043B2 (ja) | 1993-09-16 | 1999-11-15 | 高砂香料工業株式会社 | (2s)−3−{(1r,2s,5r)−[ 5−メチル−2−(1−メチルエチル)シクロヘキシル ]オキシ}−1,2−プロパンジオール,その製造方法および用途 |
| US5407665A (en) * | 1993-12-22 | 1995-04-18 | The Procter & Gamble Company | Ethanol substitutes |
| JP3241542B2 (ja) | 1994-07-29 | 2001-12-25 | 高砂香料工業株式会社 | (−)−n−イソプレゴールの精製方法及びその方法で得られた(−)−n−イソプレゴールを含有するシトラス系香料組成物 |
| WO1996011022A1 (en) * | 1994-10-05 | 1996-04-18 | Hisamitsu Pharmaceutical Co., Inc. | DRUG COMPOUNDING INGREDIENTS COMPRISING N-SUBSTITUTED-o-TOLUIDINE DERIVATIVE AND PERCUTANEOUSLY ABSORBABLE PREPARATION |
| WO1996014840A1 (en) * | 1994-11-14 | 1996-05-23 | Zyma S.A. | Use of menthyl lactate as a pain reliever |
| GB2302651B (en) | 1995-03-22 | 1999-07-28 | Teikoku Seiyaku Kk | Cold sheet |
| FR2732223B1 (fr) * | 1995-03-30 | 1997-06-13 | Sanofi Sa | Composition pharmaceutique pour administration transdermique |
| DE69625549T2 (de) * | 1995-06-27 | 2003-05-15 | Kao Corp., Tokio/Tokyo | Pflaster mit wasserlöslicher Klebeschicht |
| TR199802659T2 (xx) * | 1996-06-20 | 1999-03-22 | Lavipharm S.A. | Topikal akne tedavisi i�in bir ara� ve tedavi y�ntemi. |
| US6589994B1 (en) | 1996-08-30 | 2003-07-08 | Nps Pharmaceuticals, Inc. | Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound |
| US6244265B1 (en) | 1997-01-29 | 2001-06-12 | Peter J. Cronk | Adhesively applied external nasal strips and dilators containing medications and fragrances |
| US6769428B2 (en) | 1997-01-29 | 2004-08-03 | Peter J. Cronk | Adhesively applied external nasal strips and dilators containing medications and fragrances |
| PT1003476E (pt) * | 1997-08-11 | 2005-05-31 | Alza Corp | Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica |
| US6455080B1 (en) | 1997-12-29 | 2002-09-24 | Wm. Wrigley Jr., Company | Chewing gum containing controlled release acyclic carboxamide and method of making |
| JP3450680B2 (ja) | 1997-10-28 | 2003-09-29 | 高砂香料工業株式会社 | パラ−メンタン−3,8−ジオールの製造方法 |
| US20020013304A1 (en) * | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| AU9757398A (en) | 1997-11-27 | 1999-06-16 | Firmenich S.A. | Novel compounds derived from menthol and use as refreshing agent |
| JP4017758B2 (ja) | 1998-08-04 | 2007-12-05 | 高砂香料工業株式会社 | 冷感剤組成物 |
| US6656456B2 (en) | 1998-11-23 | 2003-12-02 | The Procter & Gamble Company | Skin deodorizing compositions |
| EP1171120A4 (en) * | 1999-02-02 | 2004-11-17 | Avon Prod Inc | PROCESS FOR ATTENUATING DISEASES RELATED TO HEAT FLUSHES AND COMPOSITIONS THEREFOR |
| US6183766B1 (en) * | 1999-02-12 | 2001-02-06 | The Procter & Gamble Company | Skin sanitizing compositions |
| EP1541039B1 (en) | 1999-03-31 | 2008-01-02 | Firmenich Sa | Flavour composition comprising cubebol and a further refreshing agent |
| US6497659B1 (en) * | 1999-04-09 | 2002-12-24 | Spacelabs Medical, Inc. | System for identifying a cable transmitting a signal from a sensor to an electronic instrument |
| US6267974B1 (en) | 1999-04-16 | 2001-07-31 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic compositions with sensate mixtures based on isopulegol |
| US6326982B1 (en) * | 1999-06-24 | 2001-12-04 | Enreach Technology, Inc. | Method and apparatus for automatically accessing web pages based on television programming information |
| WO2001017472A1 (en) * | 1999-09-08 | 2001-03-15 | Watson Pharmaceuticals, Inc. | Using quaternary ammonium salts for transdermal drug delivery |
| DE19943064B4 (de) * | 1999-09-09 | 2013-01-31 | Robert Bosch Gmbh | Verfahren zur epitaktischen Abscheidung von Atomen oder Molekülen aus einem Reaktivgas auf einer Abscheidungsoberfläche eines Substrats |
| JP4214343B2 (ja) * | 1999-10-22 | 2009-01-28 | ライオン株式会社 | パップ剤及び冷却シート剤 |
| ATE476955T1 (de) | 1999-11-12 | 2010-08-15 | Procter & Gamble | Orale zusammensetzungen enthaltend zinn-ionen |
| US6677391B1 (en) | 1999-12-08 | 2004-01-13 | The Procter & Gamble Company | Tartar control denture adhesive compositions |
| ATE380474T1 (de) | 2000-05-23 | 2007-12-15 | Nestle Sa | Verwendung von alpha-ketoenaminderivaten als kühlende mittel |
| AU2001268451A1 (en) | 2000-06-13 | 2001-12-24 | Fd Management, Inc. | Cosmetic composition for stressed skin under extreme conditions |
| WO2002013776A2 (en) * | 2000-08-11 | 2002-02-21 | The Procter & Gamble Company | Method of providing improved deodorant application to the underarm |
| US6497859B1 (en) | 2000-11-17 | 2002-12-24 | Noville Inc. | Cooling agents, pharmaceutical compositions having cooling agents and processes for making and using same |
| US20020143047A1 (en) * | 2001-01-05 | 2002-10-03 | Galer Bradley S. | Methods for treating indomethacin responsive headaches |
| US6761900B2 (en) | 2001-03-12 | 2004-07-13 | Teikoku Pharma Usa, Inc. | Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same |
| US6514484B2 (en) | 2001-03-19 | 2003-02-04 | The Procter & Gamble Company | Systems for delivering a cosmetic and/or therapeutic active to oral surfaces using an integral carrier |
| US8273367B2 (en) * | 2001-04-17 | 2012-09-25 | The Procter And Gamble Company | Articles comprising a mint odor-free cooling agent |
| CZ20033403A3 (cs) | 2001-06-25 | 2004-10-13 | Theáprocterá@Ágambleácompany | Abrazivní přípravky na čištění zubů |
| US20030175328A1 (en) * | 2002-03-06 | 2003-09-18 | Adi Shefer | Patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients into the skin |
| JP2004059474A (ja) | 2002-07-26 | 2004-02-26 | T Hasegawa Co Ltd | p−メンタン誘導体およびこれを含有する冷感剤 |
| GB0221697D0 (en) | 2002-09-18 | 2002-10-30 | Unilever Plc | Novel compouds and their uses |
| ITMI20030414A1 (it) | 2003-03-06 | 2004-09-07 | Biofarm S R L Ora Biofarmitalia S P A | Tampone con strato di gel con attivita' cosmetica o terapeutica. |
| GB0315974D0 (en) | 2003-07-08 | 2003-08-13 | Coolanalgesia Ltd | Cooling device for pain relief |
| US8062661B2 (en) | 2003-12-11 | 2011-11-22 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating skin wounds |
| US20050187211A1 (en) * | 2004-02-23 | 2005-08-25 | Wei Edward T. | N-arylsalkyl-carboxamide compositions and methods |
| US7482378B2 (en) * | 2004-05-28 | 2009-01-27 | Millenium Specialty Chemicals, Inc. | Physiological cooling compositions |
| AU2005323206C1 (en) | 2005-01-04 | 2010-01-07 | Teikoku Pharma Usa, Inc. | Cooling topical patch preparation |
| US20070259354A1 (en) | 2005-10-11 | 2007-11-08 | Senomyx, Inc. | Optimized trpm8 nucleic acid sequences and their use in cell based assays and test kits to identify trpm8 modulators |
| US20070185237A1 (en) | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive articles |
| GB0615136D0 (en) * | 2006-07-29 | 2006-09-06 | Univ Edinburgh | Induction of analgesia in neuropathic pain |
-
2005
- 2005-12-16 AU AU2005323206A patent/AU2005323206C1/en not_active Ceased
- 2005-12-16 SI SI200531465T patent/SI1833443T1/sl unknown
- 2005-12-16 JP JP2007549451A patent/JP5117196B2/ja not_active Expired - Fee Related
- 2005-12-16 CA CA2591867A patent/CA2591867C/en not_active Expired - Fee Related
- 2005-12-16 BR BRPI0519748-1A patent/BRPI0519748A2/pt not_active IP Right Cessation
- 2005-12-16 WO PCT/US2005/045835 patent/WO2006073767A1/en not_active Ceased
- 2005-12-16 MX MX2007008154A patent/MX2007008154A/es active IP Right Grant
- 2005-12-16 DK DK05854530.2T patent/DK1833443T3/da active
- 2005-12-16 US US11/305,307 patent/US8105624B2/en not_active Expired - Fee Related
- 2005-12-16 KR KR1020077014775A patent/KR20070102674A/ko not_active Ceased
- 2005-12-16 PL PL05854530T patent/PL1833443T3/pl unknown
- 2005-12-16 NZ NZ556202A patent/NZ556202A/en not_active IP Right Cessation
- 2005-12-16 ES ES05854530T patent/ES2377134T3/es not_active Expired - Lifetime
- 2005-12-16 PT PT05854530T patent/PT1833443E/pt unknown
- 2005-12-16 AT AT05854530T patent/ATE534357T1/de active
- 2005-12-16 KR KR1020097025251A patent/KR20100017599A/ko not_active Ceased
- 2005-12-16 CN CN2005800458165A patent/CN101094630B/zh not_active Expired - Fee Related
- 2005-12-16 KR KR1020117006926A patent/KR101158711B1/ko not_active Expired - Fee Related
- 2005-12-16 RU RU2007124791/15A patent/RU2375049C2/ru not_active IP Right Cessation
- 2005-12-16 CN CN2012101152892A patent/CN102670350A/zh active Pending
- 2005-12-16 EP EP05854530A patent/EP1833443B1/en not_active Revoked
-
2006
- 2006-01-02 AR ARP060100008A patent/AR055552A1/es not_active Application Discontinuation
- 2006-01-03 TW TW095100121A patent/TWI428122B/zh not_active IP Right Cessation
- 2006-01-03 TW TW101143367A patent/TW201313208A/zh unknown
-
2011
- 2011-12-06 US US13/312,744 patent/US8475836B2/en not_active Expired - Fee Related
-
2012
- 2012-06-13 JP JP2012133659A patent/JP5600141B2/ja not_active Expired - Fee Related
-
2013
- 2013-06-04 US US13/909,804 patent/US20130337032A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI428122B (zh) | 局部貼片清涼製劑及使用其之方法 | |
| JP4467437B2 (ja) | 温感パップ剤 | |
| JP2010013474A (ja) | 遅延型過敏症誘導剤を含有する局所貼付剤及び該貼付剤の使用法 | |
| JP5542665B2 (ja) | マトリックス型経皮投与剤およびその製造方法 | |
| JPWO2001047559A1 (ja) | 外用貼付剤 | |
| JP4596751B2 (ja) | 消炎鎮痛貼付剤 | |
| JP6142379B2 (ja) | 含水貼付剤 | |
| JPWO1996029062A1 (ja) | コールドシート | |
| JPH09110680A (ja) | 皮膚炎治療貼付剤 | |
| JP2003286129A (ja) | 痩身シート材 | |
| HK1172819A (zh) | 局部用降溫貼劑 | |
| HK1108350B (zh) | 局部用降溫貼劑 | |
| JP2002241747A (ja) | 冷却用組成物 |